Most Read Articles
Prof. Cheuk-Chun Szeto, Dr. Winston W. S. Fung, 25 Jan 2018
A 65-year-old lady with a background of type 2 diabetes, hyperlipidaemia and chronic immune thrombocytopenia presented to us with a 2-week history of generalized malaise and myalgia. Shortly after the onset of myalgia, she was noted to have reduced urine output and the urine was described as dark in colour. Her regular medications included prednisolone, danazol, simvastatin, metformin, and human insulin. Upon further questioning, the patient admitted that her compliance to simvastatin and danazol used to be poor. However, she recently started to take both medications regularly after repeated education.
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
Jairia Dela Cruz, 26 Jun 2018
The monoclonal antibody denosumab is safe and effective for use in patients on glucocorticoids and at risk of developing fractures, with a recent study showing that the drug performs better than risedronate in increasing bone mineral density (BMD).
Pearl Toh, 20 Mar 2018
Not only does treatment with the PCSK9* inhibitor alirocumab reduces cardiovascular (CV) events along with plunges in LDL-C levels, it was also associated with a reduced risk of all-cause mortality compared with placebo in patient with a recent acute coronary syndrome (ACS) and persistently high cholesterol despite maximal statin therapy, according to top-line results from the ODYSSEY** Outcomes trial.

R2CHOP reduces CNS relapse in diffuse large B-cell lymphoma

10 Jul 2018
Kanker darah, seperti leukemia, Hodgkin lymphona, non-Hodgkin lymphoma dan multiple myeloma

Adding lenalidomide to the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; R2CHOP) frontline therapy for diffuse large B-cell lymphoma (DLBCL) reduces the rate of central nervous system (CNS) relapse, according to a recent study.

Accessing records from two R2CHOP trials, researchers grouped 136 DLBCL patients into three groups of low (n=14; median age 56.5 years), intermediate (n=97; median age 69 years) and high (n=25; median age 69 years) risk of CNS relapse. The Kaplan-Meier method was used to estimate relapse rates, which were then compared among groups.

Only one of the participants developed isolated CNS relapse, yielding an incidence rate of 0.7 percent. The time to relapse was 10 months and the event occurred 6 months after a complete treatment response was achieved. The participant belonged to the high-risk group.

The Kaplan-Meier estimate for the 2-year relapse rate was 0.9 percent for the entire R2CHOP cohort. The corresponding values for the low-, intermediate- and high-risk groups were 0, 0 and 5.0 percent. Compared with database patients treated with R-CHOP only, the 2-year CNS relapse rate for R2CHOP was lower (0.9 percent vs 1.8 percent).

The same was true for the low- (0 percent vs 1.4 percent) and intermediate- (0 percent vs 2.2 percent) risk groups, but not the high-risk patients (5.0 percent vs 1.1 percent).

The findings support further studies on the value of lenalidomide in decreasing CNS relapse in DLBCL patients, said researchers, noting that involving clinical and molecular factors in patient risk stratification may be an effective approach.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Prof. Cheuk-Chun Szeto, Dr. Winston W. S. Fung, 25 Jan 2018
A 65-year-old lady with a background of type 2 diabetes, hyperlipidaemia and chronic immune thrombocytopenia presented to us with a 2-week history of generalized malaise and myalgia. Shortly after the onset of myalgia, she was noted to have reduced urine output and the urine was described as dark in colour. Her regular medications included prednisolone, danazol, simvastatin, metformin, and human insulin. Upon further questioning, the patient admitted that her compliance to simvastatin and danazol used to be poor. However, she recently started to take both medications regularly after repeated education.
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
Jairia Dela Cruz, 26 Jun 2018
The monoclonal antibody denosumab is safe and effective for use in patients on glucocorticoids and at risk of developing fractures, with a recent study showing that the drug performs better than risedronate in increasing bone mineral density (BMD).
Pearl Toh, 20 Mar 2018
Not only does treatment with the PCSK9* inhibitor alirocumab reduces cardiovascular (CV) events along with plunges in LDL-C levels, it was also associated with a reduced risk of all-cause mortality compared with placebo in patient with a recent acute coronary syndrome (ACS) and persistently high cholesterol despite maximal statin therapy, according to top-line results from the ODYSSEY** Outcomes trial.